Rethinking insulin

Although insulin is life-saving, its administration still carries a great deal of risk and introduces heavy burdens: constant insulin dose calculations, endless planning around meals and exercise, and nights turned sleepless by fear of dangerously low blood sugar or seizures. Although advanced medical devices and technologies are aiming to lessen some of the burden, diabetes outcomes remain poor, as currently available insulins still fail to act the way insulin does in people without diabetes.

Since insulin’s discovery, developers and engineers have primarily focused on mastering two components of insulin treatment—but novel insulin development has not yet solved a critically important factor in optimizing insulin therapy: Location.

Dosage

How much insulin a patient should administer to control blood sugar level.

Timing

How quickly or slowly it works by manipulating the insulin molecule to either increase or decrease its absorption rate and onset and duration of action.

Location

Where insulin acts and the need to re-engage the liver in glucose metabolism to mimic natural, physiological insulin action.

Breakthrough HDV technology

Diasome has developed a nanoscale, frisbee-shaped carrier known as HDV that delivers about 100 insulin molecules per disc to the liver. HDV is designed to be fully compatible with any commercially available insulin, via any delivery method, including insulin pump systems. HDV may also prove helpful in the optimization of algorithms for open or closed loop insulin delivery systems.

Pipeline

Key

planned

current

Completed

Preclinical
New Mechanism Oral HDV for T2DM
New Mechanism Oral HDV for T2DM
New Mechanism Oral HDV for T2DM
Phase 2
Oral HDV for Obesity
Oral HDV for Obesity
Oral HDV for Obesity
Injectable HDV Basal Insulin
Injectable HDV Basal Insulin
Injectable HDV Basal Insulin
Oral HDV Insulin for T1DM
Oral HDV Insulin for T1DM
Oral HDV Insulin for T1DM
Phase 2b
Oral HDV Insulin for T2DM
Oral HDV Insulin for T2DM
Oral HDV Insulin for T2DM
Injectable Mealtime HDV Insulin for T1DM
Injectable Mealtime HDV Insulin for T1DM
Injectable Mealtime HDV Insulin for T1DM
Phase 3
Injectable HDV Insulin T1DM 1H 2020 estimated
Injectable HDV Insulin T1DM 1H 2020 estimated
Injectable HDV Insulin T1DM 1H 2020 estimated

HDV technology covers the full spectrum of insulin therapies. As an additive to insulin, HDV should improve insulin's efficacy and safety for all patients regardless of insulin delivery method. HDV insulin additive may reduce the incidence of high and low blood sugar levels, therefore providing more stable blood sugar levels, while using less insulin.

Diasome has completed more than 20 human clinical trials of HDV Insulin in people with type 1 and type 2 diabetes, including studies of both oral and injectable HDV technology with different types of insulin. More than 400 people have participated in these studies. The HDV technology has been tested in the industry’s first ever Phase 2b oral insulin study and the first ever Phase 2b study of injected mealtime Liver Targeted Insulin.

For more information about Diasome's completed and ongoing trials, visit here.

Stay up-to-date with Diasome.

Enter your email address
Oops! Something went wrong while submitting the form.
10000 Cedar Avenue
Suite 6
Cleveland, OH 44106
+1.216.444.7110
info@diasome.com

Media Relations

Cherilyn Cecchini, M.D.
LifeSci Public Relations
+1.646.876.7110
ccecchini@lifescipublicrelations.com